Prior to joining Goodwin, Dr. Buchman performed an internship at Partners HealthCare in the Division of Research Ventures and Licensing, where he examined issues of commercialization and patentability related to inventions produced by Partners-affiliated research institutions. Dr. Buchman examined inventions as diverse as small molecule therapeutics for psychiatric disease treatment, novel cell culture surface materials and fabrication methods, and diagnostic devices incorporating nanotechnology.
Dr. Buchman also previously performed postdoctoral research at the Dana Farber Cancer Institute and the Massachusetts Institute of Technology, where he examined the role of epigenetic regulation in cancer biology and nervous system development. Dr. Buchman’s doctoral research at Harvard University analyzed genetic mutations in neural stem and progenitor cells and their effects on brain development and psychiatric disease.
Dr. Buchman has authored numerous peer-reviewed articles in Neuron, Cell, Genes and Development, and Nature Reviews Neuroscience. He has also presented his research at national and international conferences.